stoxline Quote Chart Rank Option Currency Glossary
  
Navidea Biopharmaceuticals, Inc. (NAVB)
0.0001  0 (0%)    05-28 14:46
Open: 0.0001
High: 0.0001
Volume: 1,230
  
Pre. Close: 0.0001
Low: 0.0001
Market Cap: 0(M)
Technical analysis
2024-06-13 4:45:04 PM
Short term     
Mid term     
Targets 6-month :  0.03 1-year :  0.04
Resists First :  0.02 Second :  0.04
Pivot price 0
Supports First :  0 Second :  0
MAs MA(5) :  0 MA(20) :  0.01
MA(100) :  0.03 MA(250) :  0.05
MACD MACD :  -0.1 Signal :  -0.1
%K %D K(14,3) :  0 D(3) :  0
RSI RSI(14): 23.9
52-week High :  0.17 Low :  0
Price, MAs and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.
[ NAVB ] has closed above bottom band by 32.4%. Bollinger Bands are 157.5% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 9 days. This is a sign that the current trend might continue.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 0 - 0 0 - 0
Low: 0 - 0 0 - 0
Close: 0 - 0 0 - 0
Company Description

Navidea Biopharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of precision immunodiagnostic agents and immunotherapeutics. It operates through two segments, Diagnostic Substances and Therapeutic Development Programs. The company develops Manocept platform to target the CD206 mannose receptor expressed on activated macrophages for a range of diagnostic modalities, including single photon emission computed tomography, positron emission tomography (PET), gamma-scanning, and intra-operative and/or optical-fluorescence detection, as well as delivery of therapeutic compounds that target macrophages, and immune-and inflammation-involved diseases. It develops NAV3-31, which has completed Phase IIb clinical trials for evaluating imaging repeatability, reproducibility, and stability, as well as the capacity of Tc99m tilmanocept imaging for treatment of anti-tumor necrosis factor alpha therapy in patients with moderate to severe rheumatoid arthritis (RA); NAV3-35 that is in a Phase IIb clinical trial for RA imaging; NAV3-33, which is in Phase III clinical trial for RA; and NAV3-32, which is Phase 2b trial for RA-involved joints. The company is also developing Tc99m tilmanocept for cardiovascular, kaposi's sarcoma, tuberculosis, and other immunotherapeutic applications. The company was formerly known as Neoprobe Corporation and changed its name to Navidea Biopharmaceuticals, Inc. in January 2012. Navidea Biopharmaceuticals, Inc. was incorporated in 1983 and is headquartered in Dublin, Ohio.

Headline News

Wed, 12 Jun 2024
Navidea Biopharma (NAVB) Reports Q2 Loss, Misses Revenue Estimates - Yahoo Lifestyle UK

Sat, 08 Jun 2024
Navidea Biopharmaceuticals (NYSE:NAVB) Research Coverage Started at StockNews.com - Defense World

Fri, 31 May 2024
Navidea Biopharmaceuticals (NYSE:NAVB) Now Covered by StockNews.com - Defense World

Fri, 01 Dec 2023
Navidea Biopharmaceuticals, Inc. and Capital Royalty Partners II, L.P. Enter Binding Settlement Agreement and Mutual ... - Business Wire

Fri, 06 Oct 2023
NYSE American halts trading on Navidea stock after delisting recommended - The Business Journals

Thu, 05 Oct 2023
Navidea Biopharmaceuticals, Inc. Announces NYSE American's Decision to Suspend Trading In Its Common Stock - Yahoo Finance

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Underperform
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Neutral
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Underperform
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Underperform
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Outperform
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Underperform
Stock Basics & Statistics
Exchange:
AMEX
Sector:
Healthcare
Industry:
Biotechnology
Shares Out -8 (M)
Shares Float 0 (M)
Held by Insiders 1.0008e+008 (%)
Held by Institutions 6.407e+007 (%)
Shares Short 0 (K)
Shares Short P.Month 0 (K)
Stock Financials
EPS -119300
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) -0.21
Profit Margin 0 %
Operating Margin -1 %
Return on Assets (ttm) 678 %
Return on Equity (ttm) 791 %
Qtrly Rev. Growth 0 %
Gross Profit (p.s.) 0
Sales Per Share 0
EBITDA (p.s.) 0
Qtrly Earnings Growth -1.013e+007 %
Operating Cash Flow 0 (M)
Levered Free Cash Flow 0 (M)
Stock Valuations
PE Ratio -0.01
PEG Ratio 0
Price to Book value -0.01
Price to Sales 0
Price to Cash Flow 0
Stock Dividends
Dividend 2.69e+006
Forward Dividend 534870
Dividend Yield 2690000000000%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android